---
document_datetime: 2025-12-02 05:38:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/obizur.html
document_name: obizur.html
version: success
processing_time: 0.1120775
conversion_datetime: 2025-12-26 17:56:40.988917
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Obizur

[RSS](/en/individual-human-medicine.xml/65611)

##### Authorised

This medicine is authorised for use in the European Union

susoctocog alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Obizur](#news-on)
- [More information on Obizur](#more-information-on-obizur-480)
- [Preventing medication errors](#preventing-medication-errors-1027)
- [More information on Obizur](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Obizur. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Obizur.

For practical information about using Obizur, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Obizur and what is it used for?

Obizur is a medicine used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII. Factor VIII is one of the proteins needed for normal clotting of the blood.

Obizur contains the active substance susoctocog alfa.

## How is Obizur used?

Obizur can only be obtained with a prescription and treatment should be supervised by a doctor with experience in the treatment of haemophilia. Obizur is available as a powder and solvent that are mixed together to make a solution for injection into a vein. The dose, and how often it is given, as well as the length of treatment, are adjusted depending on the patient's condition and requirements, and the degree of danger posed by the bleeding. For further information, see the summary of product characteristics (also part of the EPAR).

## How does Obizur work?

Patients with acquired haemophilia caused by antibodies against factor VIII have blood clotting problems, such as bleeding in the joints, muscles or internal organs. The active substance in Obizur, susoctocog alfa, works in the body in the same way as human factor VIII, but has a slightly different shape. As a result, it will not be as easily recognised by the antibodies and it can replace the human factor VIII that has been inactivated, thereby helping the blood to clot and controlling the bleeding.

## What benefits of Obizur have been shown in studies?

Obizur has been investigated in one main study involving 28 adult patients with acquired haemophilia caused by antibodies against factor VIII who were experiencing a serious bleeding episode. Obizur was not compared with any other medicine. The response to Obizur was considered positive if bleeding stopped or was reduced, while a negative response meant that the bleeding continued or worsened. All 28 patients showed a positive response within 24 hours of starting treatment with Obizur; in 24 out of 28 patients, the bleeding stopped completely.

## What are the risks associated with Obizur?

Hypersensitivity (allergic) reactions may occur with Obizur, and can include angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, hypotension (low blood pressure), feeling tired or restless, nausea (feeling sick) or vomiting, tachycardia (rapid heartbeat), tightness of the chest, wheezing and tingling sensations. In some cases, reactions become severe (anaphylaxis) and may be associated with dangerously steep falls in blood pressure. Obizur must not be used in patients who have had a severe allergic reaction to susoctocog alfa, any of its other ingredients, or hamster protein. Patients with acquired haemophilia caused by antibodies against factor VIII may develop antibodies against susoctocog alfa.

For the full list of all side effects and restrictions with Obizur, see the package leaflet.

## Why is Obizur approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Obizur are greater than its risks and recommended that it be approved for use in the EU. The CHMP noted the lack of specific treatments for acquired haemophilia caused by antibodies against factor VIII. The results of the main study showed that Obizur was effective in treating serious bleeding episodes in adults with the disorder. With regard to safety, the Committee considered that the potential for allergic reactions and the development of antibodies against the medicine is expected, and is outweighed by the beneficial effects.

Obizur has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Obizur due to the rarity of the disease. Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.

## What information is still awaited for Obizur?

Since Obizur has been approved under exceptional circumstances, the company that markets the medicine will establish and maintain a patient registry to collect and analyse short- and long-term data on the effectiveness and safety of Obizur in patients with acquired haemophilia caused by antibodies against factor VIII.

## What measures are being taken to ensure the safe and effective use of Obizur?

A risk management plan has been developed to ensure that Obizur is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Obizur, including the appropriate precautions to be followed by healthcare professionals and patients.

Additionally, the company that markets Obizur will provide healthcare professionals who are expected to use Obizur with educational material containing information on how to calculate the dose.

Further information can be found in the [Obizur : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/obizur-epar-risk-management-plan-summary_en.pdf) .

## Other information about Obizur

The European Commission granted a marketing authorisation valid throughout the European Union for Obizur on 11 November 2015.

For more information about treatment with Obizur, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Obizur : EPAR - Summary for the public

Reference Number: EMA/505987/2015

English (EN) (77.61 KB - PDF)

**First published:** 23/11/2015

**Last updated:** 23/11/2015

[View](/en/documents/overview/obizur-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-467)

български (BG) (105.13 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/bg/documents/overview/obizur-epar-summary-public_bg.pdf)

español (ES) (82.24 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/es/documents/overview/obizur-epar-summary-public_es.pdf)

čeština (CS) (102.64 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/cs/documents/overview/obizur-epar-summary-public_cs.pdf)

dansk (DA) (81.17 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/da/documents/overview/obizur-epar-summary-public_da.pdf)

Deutsch (DE) (83.45 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/de/documents/overview/obizur-epar-summary-public_de.pdf)

eesti keel (ET) (80.76 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/et/documents/overview/obizur-epar-summary-public_et.pdf)

ελληνικά (EL) (107.18 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/el/documents/overview/obizur-epar-summary-public_el.pdf)

français (FR) (81.93 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/fr/documents/overview/obizur-epar-summary-public_fr.pdf)

hrvatski (HR) (98.74 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/hr/documents/overview/obizur-epar-summary-public_hr.pdf)

italiano (IT) (81.17 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/it/documents/overview/obizur-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.29 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/lv/documents/overview/obizur-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100.7 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/lt/documents/overview/obizur-epar-summary-public_lt.pdf)

magyar (HU) (98.98 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/hu/documents/overview/obizur-epar-summary-public_hu.pdf)

Malti (MT) (103.63 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/mt/documents/overview/obizur-epar-summary-public_mt.pdf)

Nederlands (NL) (82.11 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/nl/documents/overview/obizur-epar-summary-public_nl.pdf)

polski (PL) (102.24 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/pl/documents/overview/obizur-epar-summary-public_pl.pdf)

português (PT) (82.11 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/pt/documents/overview/obizur-epar-summary-public_pt.pdf)

română (RO) (98.97 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/ro/documents/overview/obizur-epar-summary-public_ro.pdf)

slovenčina (SK) (102.08 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sk/documents/overview/obizur-epar-summary-public_sk.pdf)

slovenščina (SL) (97.24 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sl/documents/overview/obizur-epar-summary-public_sl.pdf)

Suomi (FI) (80.7 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/fi/documents/overview/obizur-epar-summary-public_fi.pdf)

svenska (SV) (81.66 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sv/documents/overview/obizur-epar-summary-public_sv.pdf)

Obizur : EPAR - Risk-management-plan summary

English (EN) (175.82 KB - PDF)

**First published:** 23/11/2015

**Last updated:** 03/02/2025

[View](/en/documents/rmp-summary/obizur-epar-risk-management-plan-summary_en.pdf)

## Product information

Obizur : EPAR - Product Information

English (EN) (438.41 KB - PDF)

**First published:** 23/11/2015

**Last updated:** 21/11/2025

[View](/en/documents/product-information/obizur-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-802)

български (BG) (674.63 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/bg/documents/product-information/obizur-epar-product-information_bg.pdf)

español (ES) (427.62 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/es/documents/product-information/obizur-epar-product-information_es.pdf)

čeština (CS) (671.07 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/cs/documents/product-information/obizur-epar-product-information_cs.pdf)

dansk (DA) (441.21 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/da/documents/product-information/obizur-epar-product-information_da.pdf)

Deutsch (DE) (551.46 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/de/documents/product-information/obizur-epar-product-information_de.pdf)

eesti keel (ET) (417.96 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/et/documents/product-information/obizur-epar-product-information_et.pdf)

ελληνικά (EL) (722.89 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/el/documents/product-information/obizur-epar-product-information_el.pdf)

français (FR) (446.03 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/fr/documents/product-information/obizur-epar-product-information_fr.pdf)

hrvatski (HR) (639.16 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/hr/documents/product-information/obizur-epar-product-information_hr.pdf)

íslenska (IS) (427.09 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/is/documents/product-information/obizur-epar-product-information_is.pdf)

italiano (IT) (429.37 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/it/documents/product-information/obizur-epar-product-information_it.pdf)

latviešu valoda (LV) (659.22 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/lv/documents/product-information/obizur-epar-product-information_lv.pdf)

lietuvių kalba (LT) (737.18 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/lt/documents/product-information/obizur-epar-product-information_lt.pdf)

magyar (HU) (609.42 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/hu/documents/product-information/obizur-epar-product-information_hu.pdf)

Malti (MT) (649.96 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/mt/documents/product-information/obizur-epar-product-information_mt.pdf)

Nederlands (NL) (508.85 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/nl/documents/product-information/obizur-epar-product-information_nl.pdf)

norsk (NO) (440.72 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/no/documents/product-information/obizur-epar-product-information_no.pdf)

polski (PL) (690.63 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/pl/documents/product-information/obizur-epar-product-information_pl.pdf)

português (PT) (449.37 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/pt/documents/product-information/obizur-epar-product-information_pt.pdf)

română (RO) (677.47 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/ro/documents/product-information/obizur-epar-product-information_ro.pdf)

slovenčina (SK) (624.06 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/sk/documents/product-information/obizur-epar-product-information_sk.pdf)

slovenščina (SL) (644.7 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/sl/documents/product-information/obizur-epar-product-information_sl.pdf)

Suomi (FI) (433.49 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/fi/documents/product-information/obizur-epar-product-information_fi.pdf)

svenska (SV) (430.64 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

21/11/2025

[View](/sv/documents/product-information/obizur-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000248614 14/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Obizur : EPAR - All Authorised presentations

English (EN) (21.57 KB - PDF)

**First published:** 23/11/2015

**Last updated:** 23/11/2015

[View](/en/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-132)

български (BG) (41.66 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/bg/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.71 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/es/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.87 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/cs/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.08 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/da/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.25 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/de/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (21.24 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/et/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.27 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/el/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_el.pdf)

français (FR) (22.18 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/fr/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.25 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/hr/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.5 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/is/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.61 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/it/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.74 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/lv/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.89 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/lt/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.15 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/hu/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.45 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/mt/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.11 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/nl/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.74 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/no/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.24 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/pl/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_pl.pdf)

português (PT) (22.06 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/pt/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.35 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/ro/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (38.19 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sk/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.89 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sl/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21.61 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/fi/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.86 KB - PDF)

**First published:**

23/11/2015

**Last updated:**

23/11/2015

[View](/sv/documents/all-authorised-presentations/obizur-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Obizur Active substance susoctocog alfa International non-proprietary name (INN) or common name susoctocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.

## Authorisation details

EMA product number EMEA/H/C/002792

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Baxalta Innovations GmbH

Industriestrasse 67

Marketing authorisation issued 11/11/2015 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Obizur : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.32 KB - PDF)

**First published:** 21/11/2025

[View](/en/documents/procedural-steps-after/obizur-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Obizur : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (183.34 KB - PDF)

**First published:** 17/05/2016

**Last updated:** 21/11/2025

[View](/en/documents/procedural-steps-after/obizur-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Obizur-H-C-2792-A31-0003 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/763977/2017

English (EN) (219.91 KB - PDF)

**First published:** 05/12/2017

**Last updated:** 05/12/2017

[View](/en/documents/variation-report/obizur-h-c-2792-a31-0003-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Obizur : EPAR - Public assessment report

Adopted

Reference Number: EMA/627966/2015

English (EN) (4.46 MB - PDF)

**First published:** 23/11/2015

**Last updated:** 23/11/2015

[View](/en/documents/assessment-report/obizur-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Obizur

Adopted

Reference Number: EMA/CHMP/471356/2015

English (EN) (70.64 KB - PDF)

**First published:** 24/07/2015

**Last updated:** 24/07/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-obizur_en.pdf)

#### News on Obizur

[Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes](/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between-classes) 15/09/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

#### More information on Obizur

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu310784) on 20 September 2010. Upon request of the marketing-authorisation holder, Obizur has now been removed from the Community register of orphan medicinal products.

#### Preventing medication errors

Obizur: educational brochure and video to be given to healthcare professionals to ensure it is used correctly

Reference Number: EMA/770206/2015

Summary:

Measures will help avoid medication errors

English (EN) (75.71 KB - PDF)

**First published:** 15/12/2015

**Last updated:** 15/12/2015

[View](/en/documents/medication-error/obizur-educational-brochure-and-video-be-given-healthcare-professionals-ensure-it-used-correctly_en.pdf)

#### More information on Obizur

- [Obizur - medication error](/en/medicines/human/medication-error/obizur)
- [Factor VIII - referral](/en/medicines/human/referrals/factor-viii)
- [EMEA-000753-PIP02-16 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000753-pip02-16)
- [241501: Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice - post-authorisation study](https://catalogues.ema.europa.eu/study/48205)
- [Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals to Assess their Knowledge on Dosing and Administration of Obizur® (Susoctocog alfa) in 6 European Countries - post-authorisation study](https://catalogues.ema.europa.eu/study/48511)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/11/2025

## Share this page

[Back to top](#main-content)